Thursday, September 10, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 16, 2026

Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

View original at finance.yahoo.com
Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results Olema Oncology On-track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L ER+/HER2- metastatic breast cancer Advanced enrollment in the OPERA-…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The November 2025 public offering enables funding operations through numerous expected value-creating events with palazestrant

    60% confidence

  • Palazestrant has potential as the combination endocrine therapy of choice in the metastatic setting

    60% confidence

  • Top-line data from OPERA-01 is expected in the fall of 2026

    60% confidence

  • Transformation into a fully-integrated oncology company is underway in preparation for the Company's first potential commercial launch in late 2027

    60% confidence

  • Commercial launch preparations are underway for a potential approval in late 2027

    60% confidence

  • Olema is on-track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial

    60% confidence

  • Initial clinical results from OP-3136 are anticipated in Q2 2026

    60% confidence

  • 2025 was a year of strong execution across the business as we advanced palazestrant as a differentiated endocrine therapy across multiple regimens

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Boom Meets Valuation Jitters: Funding Surges While Bellwether Stocks Wobble
A dense wave of AI-sector funding (Socure, Stability AI, Emerald AI, Generalist AI, Gatik, Regent Craft and others closing rounds on the same day) and strong enterprise-automation earnings (UiPath raising full-year guidance) point to continued heavy capital deployment into AI infrastructure, fintech-adjacent AI, and agentic automation. Yet Palantir's stock fell even after winning the Army's high-profile TITAN contract, and commentary (e.g., the Alphabet bull case citing AI capex and regulatory risk) signals growing investor unease about whether current AI valuations and spending levels are sustainable.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,278 source documents archived
Query this data → isubstrate.com
Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results — Source | Via News | ViaNews Market